Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Immune-related adverse event (irAE)

In one sentence

An immune-related adverse event is harm to healthy tissue attributed to treatment-related immune activity.

The intuition

The immune system needs permission to act and limits on where it acts. A treatment that changes those limits can affect healthy organs as well as a tumor. The abbreviation irAE tells you the suspected mechanism of harm. It does not tell you the affected organ, severity or treatment needed.

How it works

The term is commonly used with immune checkpoint inhibitors. These drugs interrupt regulation that helps protect healthy tissue. Immune-mediated injury can involve several interacting processes; there is no single mechanism that explains every event. The Society for Immunotherapy of Cancer (SITC) 2021 guideline distinguishes events of likely immune origin from other adverse events.

Examples include inflammation of the bowel, called colitis; the lung, called pneumonitis; or hormone-producing glands. Liver, skin, heart, kidney and nervous-system injury are also possible. Some events appear through symptoms; others first appear through laboratory changes. The suffix “-itis” means inflammation, but a symptom alone does not establish its cause. The National Cancer Institute (NCI) organ-inflammation explanation.

Onset can occur during treatment or after it ends. Resolution also varies. Some hormone-gland injuries leave lasting loss of function even after inflammation settles. An infusion calendar therefore cannot define the entire safety-observation window. Pembrolizumab prescribing information, section 5.1, SITC 2021.

New symptom or laboratory change Clinical assessment Evaluate immune-mediated injury Evaluate infection, other treatment effects and other causes Care depends on organ, severity and findings

These are assessment questions, not a home diagnostic or treatment algorithm.

Why it matters in cancer

“Side effect” is a broad everyday phrase. Adverse event means an unwanted medical occurrence reported during treatment or follow-up; it does not by itself establish that treatment caused it. An irAE is a more specific attribution. In a combination regimen, a symptom can have several plausible explanations. NCI's adverse-event reporting framework keeps occurrence, severity and attribution separate.

Clinical teams assess the organ involved, timing, severity and competing causes. The SITC guideline uses organ-specific management. Reports should also name their severity-grading framework and version. A treatment hold, medicines that suppress immune activity or replacement of a missing hormone address different problems. The care team chooses among them; readers cannot choose from the symptom name alone.

For a patient, the practical task is to use the team's reporting and urgent-care plan, and tell evaluating clinicians about current and previous immunotherapy. New or worsening breathing difficulty, chest pain or confusion warrants urgent medical assessment. Do not wait for the next infusion to report a concerning change or start immune-suppressing medicines on your own. NCI.

A worked example

Fictional patient Mina develops a new cough after finishing checkpoint treatment. “Treatment ended, so it cannot be related” closes the question too early. “It must be pneumonitis” also skips the assessment: infection and other causes remain possible. Mina reports the change using her care team's plan and shares the treatment history.

Check your understanding: Does an irAE prove that the cancer treatment is working?

Answer: No. A harm assessment does not measure tumor response or clinical benefit. Those need their own evidence.

Common confusions

  • An irAE is not every symptom that occurs during immunotherapy.
  • Cytokine release syndrome (CRS) is a systemic inflammatory syndrome associated with immune activation.
  • Immune effector cell-associated neurotoxicity syndrome (ICANS) is a separately assessed neurologic syndrome associated with immune-effector treatments. CRS and ICANS are distinct reporting frameworks, not substitute labels for checkpoint-related organ injury.
  • Stopping a treatment input does not guarantee that an immune effect has stopped.

Sources and scope

Source check: October 9, 2026. General vocabulary, timing and reporting; the case is fictional. Individual evaluation and management follow the treating team's current guidance. Expert and learner review remain pending.

Used in